NBE-THERAPEUTICS
NBE-Therapeutics is a privately owned Swiss, Basel-based biotech company that was founded in 2012. It is dedicated to developing cancer therapies to increase survival and improve the quality of life for cancer patients worldwide. The company’s immune-stimulatory therapies are based on a proprietary, highly differentiated Antibody-Drug Conjugate platform. Its ADC platform creates potent and safe immune-stimulatory ADCs with an anthracycline payload, not only directly targeting tumor cells but also inducing a long-lasting immunological anti-tumor effect.
NBE-THERAPEUTICS
Social Links:
Industry:
Biotechnology Health Care Medical Therapeutics
Founded:
2012-01-01
Address:
Basel, Basel-Stadt, Switzerland
Country:
Switzerland
Website Url:
http://www.nbe-therapeutics.com
Total Employee:
11+
Status:
Active
Contact:
+41616332230
Email Addresses:
[email protected]
Total Funding:
65.7 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API LetsEncrypt Nginx Google Maps Microsoft Azure DNS Google Maps API
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Rakuten Medical
Rakuten Medical is a Bio-technology Company.
INNOVO by Atlantic Therapeutics
INNOVO by Atlantic Therapeutics is a medical technology firm that develops pelvic floor muscle strengthening and nerve stimulation products.
BioPheresis
BioPheresis Technologies, a biotech company based in Heidelberg, Germany, offers a blood treatment system designed for cancer cure.
Calcivis
Calcivis is a biotech company that focuses on unmet needs in dentistry.
Precirix
Precirix is a platform that is developing radio-immunotherapeutic drugs for cancer patients.
Cedilla Therapeutics
Cedilla Therapeutics is a biotechnology company that develops targeted small molecules for the treatment of cancer and other diseases.
CellCentric
CellCentric is a biotechnology company that targets at deubiquitinase (DUB) enzyme for cancer therapy.
Centauri Therapeutics
Centauri Therapeutics is a UK-based biotechnology company focused on the discovery and development of life threatening diseases.
Chao Ju Ophthalmology
Chao Ju Ophthalmology is an ophthalmology treatment firm.
Combat Medical
Combat Medical are a Spanish company that have developed a new treatment for bladder cancer, and are planning to start the business in the
Eureka Therapeutics
Eureka Therapeutics is a biotechnology company focusing on immunotherapies for the treatment of cancer.
Faeth Therapeutics
Faeth Therapeutics is a cancer metabolism company that focuses on nutrition treatments for cancer patients.
Fulcrum Therapeutics
Fulcrum Therapeutics is a biotechnology company that develops new medicines to treat patients with rare genetic diseases.
Gelmetix
Gelmetix is a medical device company developing a polymer treatment for chronic lower-back pain.
Hox Therapeutics
HOX Therapeutics Ltd is a spin-off from the University of Surrey Oncology Department
INOFEA
INOFEA AG is a biotech company that offers a platform technology capable to fit enzymes in vivo and process conditions.
INSERM
Inserm is a medical research institute focusing on the development of the treatment for diseases affecting all body systems.
Barricaid
Barricaid develops a bone-anchored implant designed to close large defects in the annulus.
Ixico
Ixico is a U.K.-based company that provides clinical trial services worldwide.
MediGene
MediGene is a company that specializes in biotechnology specifically in the treatment of cancer.
Nutcracker Therapeutics
Nutcracker Therapeutics is a biotech company that develops mRNA therapeutics.
Oncomark
OncoMark is an Irish diagnostics company dedicated to develop superior tests for cancer patient stratification.
Retina Implant
Retina Implant is a biotech company which develops subretinal implants for partially sighted and blind patients.
ReViral
ReViral is a biotechnology company that develops and offers antiviral therapies for patients.
River BioMedics
River BioMedics is a biotech company that aims to develop human 3D in vitro 3D human heart tissue for pre-clinical drug testing.
SANIFIT
SANIFIT is a biotechnology company that develops treatments for patients with calcification disorders.
Sapiens Steering Brain Stimulation
Sapiens is a medical device company that delivers solutions for deep brain stimulation therapy.
SciBase
SciBase is a medical technology company that develops devices for detection of malignant melanoma.
Semma Therapeutics
Semma Therapeutics was founded to develop transformative therapies for Type 1 diabetes patients.
Spear Therapeutics
Spear Therapeutics is a privately held company that develops prodrugs for the treatment of cancer.
Tango Therapeutics
Tango Therapeutics is a biotechnology company that is developing next generation cancer therapies.
Current Advisors List
Current Employees Featured
Founder
Investors List
Boehringer Ingelheim
Boehringer Ingelheim investment in Series C - NBE-Therapeutics
PPF Group
PPF Group investment in Series C - NBE-Therapeutics
PPF Group
PPF Group investment in Series B - NBE-Therapeutics
Boehringer Ingelheim Venture Fund
Boehringer Ingelheim Venture Fund investment in Series B - NBE-Therapeutics
Novo Holdings
Novo Holdings investment in Series B - NBE-Therapeutics
Boehringer Ingelheim Venture Fund
Boehringer Ingelheim Venture Fund investment in Series B - NBE-Therapeutics
PPF Group
PPF Group investment in Series B - NBE-Therapeutics
Boehringer Ingelheim Venture Fund
Boehringer Ingelheim Venture Fund investment in Series A - NBE-Therapeutics
Boehringer Ingelheim Venture Fund
Boehringer Ingelheim Venture Fund investment in Seed Round - NBE-Therapeutics
Newest Events participated
Participated in Swiss Startup Day
on 2015-10-21 as exhibitor
Key Employee Changes
| Date | New article |
|---|---|
| 2020-08-03 | NBE-Therapeutics Appoints Bertrand Damour as Chief Executive Officer |
Official Site Inspections
http://www.nbe-therapeutics.com
- Host name: inn.host.ch
- IP address: 80.74.150.210
- Location: Neunkirch Switzerland
- Latitude: 47.6901
- Longitude: 8.4998
- Timezone: Europe/Zurich
- Postal: 8213
More informations about "NBE-Therapeutics"
Home - NBE Therapeutics
At NBE Therapeutics we strive to develop best-in-class oncology treatments to increase survival and improve quality of life for cancer patients worldwide. Through our highly innovative novel …See details»
Agreement-to-acquire-NBE-Therapeutics - Boehringer Ingelheim
Dec 10, 2020 · Ingelheim, Germany and Basel, Switzerland – 10 December 2020 – Boehringer Ingelheim today announced the signing of a binding agreement for acquiring all shares of NBE …See details»
Overview - NBE Therapeutics
NBE-Therapeutics is a privately-owned biotech company founded in 2012 and located in based in Basel, Switzerland. In December 2020 NBE-Therapeutics has been acquired by Germany …See details»
Management - NBE Therapeutics
NBE-Therapeutics AG. Technology Park Basel Hochbergerstrasse 60C CH-4057 Basel. About Us. Overview; Leadership; Scientific Advisory Board; Technology. Overview;See details»
NBE-Therapeutics AG - Swiss Biotech
NBE-Therapeutics engages in the development of “next-generation”, immune-stimulatory antibody drug conjugates (iADCs) with the objective to develop best-in-class ADC product candidates until clinical proof-of-concept in patients. …See details»
NBE-Therapeutics - Crunchbase Company Profile & Funding
NBE-Therapeutics is a privately owned Swiss, Basel-based biotech company that was founded in 2012. It is dedicated to developing cancer therapies to increase survival and improve the …See details»
NBE-Therapeutics acquired by Boehringer Ingelheim for EUR 1.18 …
Dec 10, 2020 · Boehringer Ingelheim today announced the signing of a binding agreement for acquiring all shares of NBE-Therapeutics, a private, clinical-stage Swiss biotechnology …See details»
NBE-Therapeutics AG - LinkedIn
At NBE Therapeutics we strive to develop best-in-class oncology treatments to increase survival and improve quality of life for cancer patients worldwide. Through our highly innovative novel...See details»
Boehringer Ingelheim to Acquire NBE-Therapeutics for EUR 1.18 …
Dec 10, 2020 · By combining its world-class, in-house research and development with that of highly innovative biotechnology companies, Boehringer Ingelheim is developing innovative …See details»
Boehringer to acquire NBE-Therapeutics for $1.43bn
Dec 11, 2020 · Boehringer Ingelheim has signed a binding agreement to acquire all shares of clinical-stage Swiss biotechnology company NBE-Therapeutics for a total of €1.18bn ($1.43bn) to enhance its cancer pipeline portfolio. The deal …See details»
Boehringer Ingelheim to acquire ADC firm NBE-Therapeutics
Dec 17, 2020 · Boehringer Ingelheim will enter the antibody-drug conjugate (ADC) field by acquiring the Swiss firm NBE-Therapeutics for about $1.4 billion. NBE conjugates antibodies …See details»
Boehringer to acquire Swiss biotech firm NBE-Therapeutics for …
Boehringer Ingelheim has agreed to acquire clinical-stage Swiss biotechnology firm NBE-Therapeutics for €1.18bn for enhancing its cancer pipeline portfolio.See details»
BI to Acquire NBE-Therapeutics | Boehringer Ingelheim US
Ingelheim, Germany and Basel, Switzerland – 10 December 2020 – Boehringer Ingelheim today announced the signing of a binding agreement for acquiring all shares of NBE-Therapeutics, a …See details»
NBE Therapeutics Company Profile 2024: Valuation, Investors ...
Developer of an immune-stimulatory antibody-drug conjugate platform designed to improve the treatment options for cancer patients.See details»
NBE-Therapeutics AG - Tech Park Basel
NBE-Therapeutics utilizes a portfolio of in-house developed, externally acquired, and in-licensed novel patent families for the development of novel, best-in-class antibody drug conjugates …See details»
Acquisition agreement with Boehringer Ingelheim for NBE …
Dec 10, 2020 · PPF Group, an international investment group, today announced the signing of a binding agreement to sell its stake in NBE-Therapeutics to Boehringer Ingelheim. NBE …See details»
SOTIO and NBE-Therapeutics sign collaboration and license...
Oct 20, 2016 · Basel, Switzerland & Prague, Czech Republic – NBE-Therapeutics AG and SOTIO a.s. today announced that the companies have entered into a collaboration for the …See details»
NBE-Therapeutics - Funding, Financials, Valuation & Investors
NBE-Therapeutics is a biotech company that develops oncology treatments for cancer patients.See details»
News - NBE Therapeutics
NBE-Therapeutics is committed to developing best-in-class therapies to increase survival and improve quality of life for cancer patients worldwide. NBE-Therapeutics provides an …See details»
NBE-Therapeutics Commences First Clinical Study of Anti-ROR1 …
Oct 26, 2020 · NBE-Therapeutics' best-in-class iADC® platform creates highly potent, safe and immune-stimulatory ADCs with a novel anthracycline payload, which have been shown to …See details»